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One of the most potent pro-fibrotic cytokines is transforming growth factor beta 1 (TGFβ1), 
which is actively involved in the transition of fibroblasts into myofibroblasts. The latter cells 
are responsible for the hallmark of fibrosis, namely the pathological accumulation of a 
collagen-rich extracellular matrix (ECM) [1, 2]. Fibrosis can eventually result in organ failure 
and death. Currently, several strategies and anti-fibrotic candidates are under preclinical 
and clinical development, but so far no effective treatment has been reported that can 
abrogate fibrosis. This thesis investigated the anti-fibrotic potential of several biologicals 
and low molecular weight compounds on human fibroblasts from different organs (skin, 
lung) and ages (newborn, adult). 
Inhibition of pro-fibrotic events by interleukin-1β 
It has been postulated that interleukin-1β (IL1β) has a damaging role in fibrosis [3-8]. 
However, studies investigating the direct effect of IL1β on fibroblasts with or without 
TGFβ1 are scarce; the role of IL1β is therefore poorly understood. In Chapter II, we have 
investigated the direct effects of IL1β on dermal and lung fibroblasts in the presence or 
absence of TGFβ1. Our study provides evidence that IL1β alone is unable to induce the 
formation of actin stress fibers (αSMA and SM22α) or to enhance collagen type I synthesis, 
but stimulates the expression of MMP1, -2 and -14, irrespective the presence or absence 
of TGFβ. Even more interesting is that IL1β is able to reduce the TGFβ1-induced expression 
of the myofibroblast markers αSMA and SM22α and the deposition of collagen type I. In 
addition, IL1β reduced the TGFβ-induced expression (and consequently the total activity) 
of lysyl oxidase, an enzyme that is required for collagen cross-linking. Inhibiting lysyl 
oxidase activity levels has been reported to have an anti-fibrotic effect [9, 10]. Finally, IL1β 
reversed, albeit only partially, αSMA and SM22α synthesis and collagen type I expression 
in TGFβ1-activated fibroblasts. These results suggest that IL1β can potentially attenuate 
the severity of fibrosis, especially in a late stage where TGFβ1 is abundantly present.  
The differentiation of fibroblasts into myofibroblasts is dependent on the activation of the 
non-canonical sonic Hedgehog pathway, especially with respect to the transcription factor 
Glioma-associated oncogene homolog 1 (GLI1) [11, 12]. We observed, as expected, an 
upregulation of GLI1 by TGFβ1, but this upregulation was reduced by IL1β. This explains, at 
least in part, the inhibitory effect of IL1β on TGFβ1-induced myofibroblast formation. 
The use of paracrine factors secreted by fetal and adult stem cells to attenuate 
myofibroblast formation and collagen accumulation 
In preclinical models, fetal and adult mesenchymal stem cells can attenuate fibrosis [13, 
14]. Due to the complexity of the tissue micro-environment it is quite challenging to 
investigate the effects of paracrine signaling of stem cells on (myo)fibroblasts activities in 
vivo. Therefore, we investigated the direct effect of paracrine factors of mesenchymal stem 
cells as secreted in culture medium on myofibroblast formation in vitro. This was done for 
both fetal stem cells (as obtained from amniotic fluid) and adult stem cells (as obtained 




from adipose tissue) in order to compare the magnitude of anti-fibrotic effects exerted by 
these cells. Such a comparison is also potentially interesting having in mind that fetal skin 
wounds heal without scarring while healing of adult tissue leads to scar formation/fibrosis 
[15-17].  
In Chapter III, we reported that conditioned medium of amniotic fluid-derived human 
mesenchymal stem cells (cmAFSCs) strongly counteracts the TGFβ1-induced formation of 
αSMA stress fibers and the synthesis of the ECM proteins collagen type I and III, tenascin C, 
and fibronectin in dermal fibroblasts (donor age 27 and 73 years). Interestingly, 
conditioned medium of adipose tissue-derived adult human mesenchymal stem cells 
(cmADSCs) did not reveal such an inhibitory effect. Furthermore, cmAFSCs showed the 
ability to reverse pre-existing myofibroblasts into fibroblasts. Similarly, cmADSCs was also 
able to reverse pre-existing myofibroblasts into fibroblasts. These results point towards a 
strong anti-fibrotic potential (especially in terms of inhibition of myofibroblast formation 
and ECM deposition) of conditioned medium from fetal mesenchymal stem cells on 
fibroblasts cultured in a pro-fibrotic environment. Compared to cmAFSCs, cmADSCs 
showed only limited capacities to suppress myofibroblast formation and collagen synthesis. 
The paracrine factors which are involved in the strong anti-fibrotic properties of cmAFSCs 
are unknown. However, it has been shown that cmAFSCs contains a high level of basic 
fibroblast growth factor (bFGF = FGF2) and that bFGF is hardly present in the conditioned 
medium of adult mesenchymal stem cells [18]. Previous studies reported, in a different 
context, that bFGF is able to attenuate the synthesis of αSMA and collagen [19-21]. Thus, 
bFGF might be a potential candidate to explain for what we have observed for cmAFSCs. By 
using a bFGF neutralizing antibody we indeed showed that the strong suppression of αSMA 
stress fiber by cmAFSCs is partially due to bFGF. Remarkably, no effect was observed in the 
synthesis of collagen type I, suggesting that a molecule other than bFGF is involved in 
blocking the collagen type I protein synthesis. Further investigations are needed to fully 
understand the mechanism.  
 
TGFβ1 and TGFβ3 show similar pro-fibrotic phenomenon on neonatal and adult 
fibroblasts 
 
The expression of TGFβ is crucial with regard to scarless or scar formation during wound 
healing.  An important mechanism distinguishing scarless from scarred wound healing is 
the balance between the different TGFβ isoforms. Adult skin wound healing is 
characterized by the presence of high levels of TGFβ1 and TGFβ2 which cause 
scarring/fibrosis. On the other hand, scarless fetal wound healing exhibit a high level of 
TGFβ3 compared to the other two isoforms. In preclinical and clinical studies, addition of 
TGFβ3 decreases scar formation in neonatal and adult wound healing [22-26]. In contrast, 
in vitro studies indicate that TGFβ3 promotes the formation of myofibroblasts and ECM, 
the hallmark of scarring/fibrosis [27-30]. These observations are in contrast with the anti-
scarring properties of TGFβ3 in vivo. However, limited data are available regarding the 




direct effects of TGFβ3 regarding the synthesis of extracellular matrix by human dermal 
fibroblasts of different ages. 
In chapter 4, we systematically compared the effects of TGFβ1 and TGFβ3 in neonatal, 
adult, and older adult skin fibroblasts on ECM molecules and cytokines involved in 
scarring/fibrosis. In our study, we showed that both TGFβ1 and TGFβ3 increased the 
protein expression of fibronectin, tenascin C and lysyl hydroxylase 2 in all fibroblast types. 
Additionally, TGFβ1 and TGFβ3 were able to upregulate the formation of α-smooth muscle 
actin and collagen type I in neonatal and adult fibroblasts. Furthermore, mRNA expression 
of FN1, TNC1, PLOD2, PDGFA, VEGFA and FGF2 was affected in a similar way by TGFβ1 and 
TGFβ3 on neonatal, adult and older adult fibroblasts. Our findings indicate that TGFβ3 can 
induce a fibrotic response in a fashion similar as TGFβ1, which are in line with previous 
reports on mice and rats. In mice, fetal and adult skin fibroblasts exhibit an upregulation of 
Ctgf and Smad7 expression, and a down-regulation of Smad3 expression, when treated 
with TGFβ1, -β2 or -β3 [31]. In rats, treatment of adult tendon fibroblasts with TGFβ1 or 
TGFβ3 resulted in an increase in mRNA levels of Col1a1 and Col3a1 [32]. These 
observations suggest TGFβ3 behaves, like TGFβ1, as a pro-fibrotic cytokine in vitro. 
 
Inhibition of NF-κB to inhibit myofibroblast formation and collagen deposition 
 
The transformation of fibroblasts into myofibroblasts is shown to be dependent on the 
activation of the Nuclear Factor kappa B (NF-κB) pathway [33-36], particularly NF-κB 
subunit p65 (= RelA) [35-38]. Several NF-κB pathway inhibitors have been studied in pre-
clinical models to reduce fibrotic processes [37, 38]. Unfortunately, in all these studies, 
inadequate protective properties of these inhibitors have been reported. Therefore, 
another therapeutic compound that interferes with the NF-κB pathway is necessary to 
decrease or even prevent the development of fibrosis.  
We tested two different low molecular weight NF-κB inhibitors, namely CAPE (in Chapter V) 
and ACHP (in Chapter VI) on lung and dermal fibroblasts stimulated with TGFβ1. Our data 
revealed that both CAPE and ACHP are able to completely abolish the TGFβ1-induced 
synthesis of αSMA stress fibers together with the production of collagen type I in either 
type of fibroblast. Furthermore, a post-treatment with these inhibitory agents on TGFβ1-
stimulated fibroblasts partially reversed the expression of αSMA and collagen type I. These 
findings indicate that the NF-κB pathway indeed plays an important role in myofibroblast 
activity and that the inhibition of the NF-κB pathway still seems to be an attractive 
therapeutic tool to attenuate and reverse fibrotic processes. 
As was described above for chapter 2, expression of GLI1 is required to induce 
myofibroblast formation [11, 39]. Since GLI1 expression as conducted by TGFβ1 requires 
GLI2 expression, we measured both GLI1 and GLI2 mRNA levels, and revealed that 
fibroblasts treated with CAPE show decreased levels of both transcription factors. This will 
certainly contribute to the abolishment of myofibroblast formation by CAPE. Our data also 
indicate that there might be a signalling cross-talk between NF-κB and the non-canonical 




sonic Hedgehog pathway in pro-fibrotic conditions, which however requires further studies 
for definite proof. 
Synthesis of collagen type I and αSMA and lysyl hydroxylase 2 are uncoupled 
One of the observations in this thesis was that there is not a 1:1 correlation between the 
expression of αSMA and collagen type I in anti-fibrotic conditions. In Chapters V and VI, we 
showed that a reduction in collagen type I synthesis after a post-treatment of CAPE or 
ACHP was not reflected in a down-regulation of αSMA expression. In Chapter III, we found 
that neutralization of bFGF partially reversed the suppression of αSMA by cmAFSCs, while 
the deposition of collagen type I was unchanged. This suggests that the expression of αSMA 
and collagen type I are separately regulated and can also be uncoupled from each other. 
This finding is in line with previous evidence that myofibroblasts of αSMA knockout mice 
are still capable of producing collagen [40].  
Another uncoupling of expression is observed between the expression of collagen type I 
and lysyl hydroxylase 2 (encoded by PLOD2). Lysyl hydroxylase 2, a collagen-modifying 
enzyme, plays a crucial role in the stability of the collagen fibril. In fibrosis, an elevated level 
of lysyl hydroxylase 2 has been reported [41-44], explaining the higher level of pyridinoline 
cross-links which results in collagen that is difficult to degrade. Interestingly, when collagen 
type I synthesis was attenuated (with IL1β, cmAFSCs, CAPE and ACHP), we observed a 
strong expression of lysyl hydroxylase 2 (Chapters II, III, V and VI). The reason for this up-
regulation is unknown. 
 
Fibroblast diversity and fibrosis 
 
A relevant finding of this thesis is further that fibroblasts from different origins do not 
always react identical. In Chapters II, V and VI, we have observed major discrepancies 
between lung and dermal fibroblasts. For example, in Chapter II, we showed that the 
extent of suppression of COL1A1 mRNA levels was more prominent in lung fibroblasts 
compared to dermal fibroblasts when the cells where treated with IL1β after TGFβ1 
stimulation. Furthermore, the magnitude of up-regulation of COL3A1 and MMP1 mRNA 
levels by IL1β after the pre-treatment with TGFβ1 showed a large difference between 
these two fibroblast types.   
After TGFβ1-stimulation, a post-treatment with CAPE (Chapter V) or ACHP (Chapter VI) 
reduced the number of fibroblasts positive for αSMA in dermal fibroblasts, but not in lung 
fibroblasts. In addition, the co-presence of CAPE with TGFβ1 synergistically upregulated 
the gene expression of COL1A2 and SNAIL1 in dermal fibroblasts, whereas a down-
regulation was observed in lung fibroblasts. Moreover, the magnitude of response towards 
CAPE regarding mRNA expression of PLOD2 varies strikingly between lung and dermal 
fibroblasts. In dermal fibroblasts, mRNA level of PLOD2 was strongly increased either with 
CAPE alone or in combination with TGFβ1, whereas under similar conditions a relatively 
modest up-regulation of PLOD2 was detected in lung fibroblasts. The behavioral difference 
between dermal and lung fibroblasts is in line with the findings that fibroblasts derived 




from different organs show large differences in phenotypic properties, as reflected by 
marked differences in gene expression patterns [45, 46]. These phenotypical differences 
should be taken into account in the search for anti-fibrotic agents: an inhibitor may not 
have the desired effect in all organ systems due to the different response of the 
fibroblasts. 
Another interesting observation was made in Chapter VI. The expressions of all three 
PLODs in dermal fibroblasts were reduced by ACHP alone (compared to control), or ACHP + 
TGFβ1 (compared to TGFβ1), while no such inhibition was detected in lung fibroblasts. It 
thus appears that the pathways that regulate the expression of these three PLODs might 
differ at least partly in lung and dermal fibroblasts. Clearly, the origin of fibroblasts should 
be taken in consideration when studying pathways.   
Synthesis of collagen: importance of mRNA and protein expression in myo(fibroblast) 
biology 
Major differences were noticed between mRNA levels and protein synthesis levels of 
collagen in fibroblasts, showing the need of protein data to draw reliable conclusions in 
fibrosis research. In Chapter III, a down-regulation of COL1A1 mRNA was seen in adult 
fibroblasts under the influence of cmADSCs, but the protein content of collagen type I was 
unchanged upon such treatment. An opposite phenomenon was seen regarding collagen 
type III. mRNA levels of COL3A1 were not decreased under the influence of cmADSCs, 
although a significant suppression was noticed in collagen type III protein synthesis in 
fibroblasts. In Chapter IV, the mRNA level of COL1A1 did not show an upregulation in old 
fibroblasts upon treatment with TGFβ3, although a major increase is seen in protein 
production. In Chapter V, our data show that the mRNA level of COL1A1 and COL1A2 in 
dermal fibroblasts was highly upregulated when stimulated with TGFβ1 + CAPE compared 
to non-stimulated fibroblasts, but that these fibroblasts failed to produce collagen. 
Therefore, studies regarding the anti-fibrotic properties of compounds should always take 
protein expression data into account, not gene expression levels.  
Future perspectives 
Since no approved drugs are currently available that can attenuate or reverse the fibrosis, 
there is a need to develop a pharmacological agent that can halt the progression of fibrotic 
disorders. In this thesis we show that ACHP and CAPE have strong anti-fibrotic properties in 
vitro. However, these compounds should first be tested in animal models to verify its 
potential in anti-fibrotic strategies in complex tissue-microenvironments, where different 
cells types are involved.    
We also showed that the conditioned medium from mesenchymal stem cells of fetal origin 
has high anti-fibrotic effects on skin myofibroblasts. The mechanism involved to induce 
such a strong anti-fibrotic potential is partially due to bFGF. Additional research should be 
performed to deciphere which other paracrine factors are responsible for the anti-fibrotic 
paracrine properties of mesenchymal stem cells.   
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